NOTCH1 and head and neck squamous cell carcinoma: To evaluate the activity and tolerability of NOTCH1 inhibitor DAPT in HNSCC in vivo, pilot dosage studies were conducted using CAL27 as human HNSCC CAL27 xenograft models.